Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic StudyICU에 입원한 COVID-19 환자에서 토실리주맙의 고정 용량을 향하여: 관찰 인구 약동학 및 기술 약력학 연구의 결과Observational Study Published on 2022-02-012022-09-12 Journal: Clinical pharmacokinetics [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] added Admission age Analysis applied AUC average clearance Concentration concomitant therapy coronavirus disease covariate COVID-19 COVID-19 patients COVID-19 treatment guidelines Dexamethasone dexamethasone 6 mg distribution dose dose administration Dosing dosing schedules eligible elimination rate enrolled Evidence Final first dose fixed fixed dose ICU identify IMPROVE increase indications intensive care intravenous tocilizumab investigated linear mechanical ventilation mixed-effects model nasal obesity Older Open-label outcome oxygen support parameter pathway Patient patients performed Pharmacodynamic pharmacokinetic plasma sample polymerase chain Population provide raised Randomized controlled trial receptor REMAP-CAP Result risk factor Safe saturated severe COVID-19 shown Support survival Tocilizumab Variability Volume was performed [DOI] 10.1007/s40262-021-01074-2 PMC 바로가기 [Article Type] Observational Study
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication InhibitorSARS-CoV-2 복제 억제제인 렘데시비르의 약동학, 약력학 및 약물 상호작용 프로필Review Published on 2021-05-012022-09-11 Journal: Clinical pharmacokinetics [Category] SARS, 치료기술, 치료제, [키워드] accumulate Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Analysis approval approvals Cell children Clinical data clinical dosing clinically Concentration coronavirus coronavirus disease Coronavirus disease 2019 country COVID-19 dose dose regimen doses drug-drug interaction Drug-drug interactions eliminated enzyme followed by GS-441524 healthy healthy volunteers Hospitalized in vitro inducer infected with COVID-19 inhibitor inhibitors intravenous Intravenous administration linear Loading dose maintenance dose metabolite mononuclear cells multiple dose multiple doses nucleoside once daily parenteral route Participants Patient patients with COVID-19 Peripheral blood Peripheral blood mononuclear cells Pharmacodynamic pharmacokinetic pharmacokinetics Phase I plasma polymerase predicted profile rationale RDV regimen Remdesivir Replication Result Ribonucleic acid SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe coronavirus disease therapeutic Treatment treatment of COVID-19 triphosphate Veklury was selected [DOI] 10.1007/s40262-021-00984-5 PMC 바로가기 [Article Type] Review
Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis BReview Published on 2019-10-012023-06-19 Journal: Expert opinion on drug metabolism & toxicology [Category] B형 간염, [키워드] interferon mechanism Pegylated interferon Pharmacodynamic Pharmacokinetic. [DOI] 10.1080/17425255.2019.1678584 PMC 바로가기 [Article Type] Review